Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MyMD Pharmaceuticals, Inc. - Common Stock (NQ:MYMD)

1.820 UNCHANGED
Last Price Updated: 3:38 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MyMD Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Set to Join Russell Microcap® Index
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Schedules Business Update Conference Call
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds
From MyMD Pharmaceuticals, Inc.
Via Business Wire
News headline image
MyMD Pharmaceuticals Begins Trading on Nasdaq
From MyMD Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.